Striatum methamphetamine

Eyerman, D.J., Yamamoto, B.K. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther. 312 160, 2005. 

Lin, X.H., Hashimoto, T., Kitamura, N. et al. Decreased calcineurin and increased phosphothreonine-DARPP-32 in the striatum of rats behaviorally sensitized to methamphetamine. Synapse. 44 181, 2002. 

Chen, PC., Chen, J.C. Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats. Neuropsychopharmacology. 30 538, 2005. 

Bronstein, D.M., Pennypacker, K.R., Lee, H., Hong, J.S. Methamphetamine-induced changes in AP-1 binding and dynorphin in the striatum correlated, not causally related events Biol. Signals. 317, 1996. 

Muratake, T., Toyooka, K., Hayashi, S. et al. Immunohistochemical changes of the transcription regulatory factors in rat striatum after methamphetamine administration. Ann. N.Y. Acad. Sci. 844 21, 1998. 

Bowyer, J.F., Tank, A.W., Newport, G.D. et al. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J. Pharmacol. Exp. Ther. 260 817, 1992. 

Harvey, D.C., Lacan, G., Melegan, W.R Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp. Brain Res. 133 349, 2000. 

Ito, C., Onodera, K., Sakurai, E., Sato, M., and Watanabe, T. (1996). Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J. Pharmacol. Exp. Ther. 279(1), 271—276. 

Camp DM, Browman KE, Robinson TE (1994) The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res 665 180-193. 

Fig. 14. In vivo PET images from Volkow et al. (2001a) of the distribution volume of [llC]d-threo-methylphenidate (label dopamine transporter sites) in a control and a methamphetamine abuser. The images represent the level of the striatum (left) and the cerebellum (right) in a normal control and a methamphetamine abuser evaluated twice, during short and protracted abstinence. Note the reduction of striatal dopamine transporter binding following early abstinence and the reversal to more normal levels in binding in the methamphetamine abuser with protracted abstinence.

Hashimoto S, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, Iyo M. Protective effects of N-acetylcysteine on the reduction of dopamine transporters in the striatum of the monkeys treated with methamphetamine. Neuropsychopharmacology 2004 29 2018-13. 

The first line of a-synuclein knock-out mice displays a reduced level of DA in the striatum (Abeliovich et al., 2000), however, behavioural assessment did not reveal any major impairment. The second line of a-synuclein-null mice generated by Dauer et al. (2002) were completely resistant to MPTP intoxication, likely due to an incapacity of MPP+ to inhibit complex I in these mice. A third line of a-synuclein knock-out mice generated showed a partial protection to MPTP-induced striatal DA loss and an increased methamphetamine-induced DA depletion (Schluter et al., 2003). 

The effects of cerebral injections of methamphetamine on striatal TPH activity were also investigated (figure 1). In an anesthetized rat, systemically administered methamphetamine (10 mg/kg) decreased striatal TPH activity. However, bilateral injections of methamphetamine into the neostriatum (100 g) failed to decrease striatal TPH activity 3 hours after treatment. To determine whether multiple areas of the brain are involved in methamphetamine-induced changes in striatal TPH, microinjections of methamphetamine were administered into the substantia nigra or lateral midbrain and into the striatum. Three hours after treatment, injections of methamphetamine into the striatum (100 g) and the substantia nigra (25 g) or the lateral midbrain (area of B9 serotonergic cell bodies) (50 g) did not reduce TPH activity in the neostriatum. 

Rollema, H. DeVries, J.B. Westerink, B.H.C. VanPutten, F.M.S. and Horn, A.S. Failure to detect 6-hydroxydopamine in rat striatum after the dopamine releasing drugs dexamphetamine, methamphetamine, and MPTP. Eur J Pharmacol 132 65-69, 1986. 

Semba J, Wakuta M, Suhara T, Long-term suppression of methamphetamine-induced c-Fos expression in rat striatum by the injection of c-Fos antisense ohgodeox3mucleotides absorbed in water-absorbent pol5mier. Psychiatry Clin... 

---